ASH 2018: Dr. Kay on the ECOG trial: Frontline FCR versus Ibrutinib plus rituximab for chronic lymphocytic leukemia) in Patients < 70 years old At ASH 2018, the CLL game-changer was the late-breaking abstract on the large phase 3 trial that compared the gold... September 12, 20192018 ConferencesBy Brad Hedrick
ASH 2018: Dr. Lindsey Roeker on the CORE trial for CLL (chronic lymphocytic leukemia) Patients We have a great many choices of medications to treat our chronic lymphocytic leukemia, but how to best use and... September 12, 20192018 ConferencesBy Brad Hedrick
ASH 2018: Dr. Nabhan on his Career Path as related to chronic lymphocytic leukemia (CLL) Research At ASH 2018, Dr. Nabhan discusses his change from 20 years of directly caring for patients and doing interventional research... September 8, 20192018 ConferencesBy Brad Hedrick
ASH 2018: Dr. Chadi Nabhan on the Economic Impact of Venetoclax versus Chemo-immunotherapy (CIT) and Chemotherapy (CT) in CLL We recently posted Dr. Nabhan’s research on the cost of ibrutinib versus CIT and CT in chronic lymphocytic leukemia. At ASH... September 8, 20192018 ConferencesBy Brad Hedrick
ASH 2018: Dr. Mato on Testing Before Treatment in chronic lymphocytic leukemia (CLL) We have to know our enemy before we decide how to best target therapy. That is why testing before treatment... August 26, 20192018 Conferences, Test Before TreatBy Brad Hedrick
ASH 2018: Dr. Maddali on Drug Development in Cancer Dr. Kamala Maddali has a diverse background in the pharmaceutical industry and gives us an overview on how a new... August 25, 20192018 ConferencesBy Brad Hedrick
ASH 2018: Dr. Nabhan on Patient Reported Outcomes (PROs) in Malignant Hematology At ASH 2018, Dr. Nabhan discussed the importance of Patient Reported Outcomes or PROs in not only research, but in... August 11, 20192018 ConferencesBy Brad Hedrick
ASH 2018: Dr. Chadi Nabhan on the Cost of Ibrutinib vs. Chemo vs Chemoimmunotherapy in CLL (chronic lymphocytic leukemia) At ASH 2018 like all big hematology congresses, research is presented that is preclinical basic science, research that reports the... August 11, 20192018 ConferencesBy Brad Hedrick
ASH 2018: Dr. Neil Kay on how Stromal Cells Keep CLL (chronic lymphocytic leukemia) Cells Alive in the Bone Marrow and How we Can Intervene At ASH 2018 in San Diego, CA, I interviewed Dr. Neil Kay out of Mayo Clinic, Rochester, MN, an innovative... August 11, 20192018 ConferencesBy Brad Hedrick
ASH 2018: Lorna Warwick on the Value of Being a Properly Informed Patients Lorna Warwick, the CEO of the Lymphoma Coalition (LC), discussed her organization’s research that was presented at ASH 2018. LC is... August 5, 20192018 ConferencesBy Brad Hedrick
